UBS Group AG Has $4.06 Million Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH

UBS Group AG lifted its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 28.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 254,672 shares of the biotechnology company’s stock after purchasing an additional 55,924 shares during the quarter. UBS Group AG owned 0.19% of Aurinia Pharmaceuticals worth $4,062,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Aurinia Pharmaceuticals in the 3rd quarter worth about $48,000. State of Alaska Department of Revenue bought a new stake in shares of Aurinia Pharmaceuticals in the 3rd quarter worth about $91,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Aurinia Pharmaceuticals by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 1,318 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Aurinia Pharmaceuticals by 32.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 3,191 shares during the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Aurinia Pharmaceuticals in the 3rd quarter worth about $137,000. Institutional investors own 36.83% of the company’s stock.

Insider Buying and Selling

In related news, Director Kevin Tang acquired 516,439 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $13.99 per share, with a total value of $7,224,981.61. Following the acquisition, the director directly owned 11,845,939 shares in the company, valued at $165,724,686.61. The trade was a 4.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 12.20% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Stock Down 1.5%

AUPH opened at $15.22 on Friday. The firm’s 50-day simple moving average is $15.38 and its 200-day simple moving average is $15.21. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.01 and a current ratio of 5.55. Aurinia Pharmaceuticals Inc has a twelve month low of $7.28 and a twelve month high of $16.88. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 7.01 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The firm had revenue of $77.71 million for the quarter, compared to analyst estimates of $76.98 million. Equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $17.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.